MA-EXAGRID
15.9.2020 14:02:11 CEST | Business Wire | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the release of software Version 6.0, which begins shipping on September 18, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005278/en/
Key features include:
New Retention Time-Lock for Ransomware Recovery
Retention Time-Lock is a revolutionary approach to protecting backup retention data to enable fast and easy recovery from ransomware.
- ExaGrid’s two-tier architecture includes a network-facing tier and a non-network-facing tier. ExaGrid alone controls the non-network-facing tier, creating a tiered air gap.
- Backups are written to the network-facing-tier for fast backup performance. The most recent backups are kept in their full undeduplicated form for fast restores.
- Data is adaptively deduplicated (for storage cost efficiency) into the non-network-facing tier for long-term retention data. Organizations can have as many days, weeks, months, or years of retention as they require. There is no limit to the number of version retention copies that can be saved.
- In addition to the long-term retention, ExaGrid offers a policy-driven approach allowing for any delete requests issued to the network-facing tier to be delayed in the non-network-facing tier for a specified number of days, so that backup data will not be deleted when a hacker takes control of the backup application or backup storage.
- If encrypted data is sent to the network-facing tier, or if any of its data is encrypted, ExaGrid’s repository is protected as all the deduplication objects are immutable because they are never modified.
ExaGrid assumes the hackers will take control of the backup application or the backup storage and will issue delete commands for all backups. ExaGrid has the only non-network-facing tiered backup storage solution (a tiered air gap) with delayed deletes and immutable deduplication objects. This unique approach ensures when a ransomware attack occurs, data can be easily recovered or VMs booted from the ExaGrid Tiered Backup Storage system. Not only can the primary storage be restored, but all retained backups remain intact.
“ExaGrid’s Version 6.0 provides our customers with a new strategy for ransomware recovery: ExaGrid’s Retention Time-Lock, which prevents hackers from deleting data stored in our system’s repository tier as all deletes are delayed by a policy setting. This unique approach allows customers to recover data in the event that the primary storage has become compromised by ransomware or malware,” said Bill Andrews, ExaGrid’s President and CEO. “Unlike other approaches, which require the purchase of an additional storage unit, our approach only requires that customers allocate 2% to 10% of additional repository storage in their existing system with an adjustable delay period, which is in line with our goal of offering the most cost-effective solutions to our customers.”
Security Enhancements (in addition to Ransomware Recovery), New UI Platform, and Other Highlights of Version 6.0
Version 6.0 includes the following security enhancements:
- New security officer role governs any changes to the Retention Time-Lock policy
- Optional Two-Factor authentication in web-based user interface using any OAUTH-TOTP app
- Additional control over SSH access
- Utilize Active Directory credentials from trusted domains to control share and user interface access
- New operator role for day to day operations reduces the need for administrator access.
- Security checklist for quick and easy implementation of best practices
- Automatic user interface logout after a period of inactivity
Version 6.0 includes the following additional features:
- User interface improvements provide intuitive details about how the ExaGrid system’s storage capacity is being utilized
- Streamlined navigation experience
- Deduplication and replication performance improvements across multiple backup applications
ExaGrid’s Unique Approach: Tiered Backup Storage
Disk-cache Landing Zone (Performance Tier)
- ExaGrid writes directly to disk for the fastest backup performance
- ExaGrid restores directly from disk for the fastest restores and VM boots
Long-term Retention Repository (Retention Tier)
- ExaGrid tiers long-term retention to a deduplicated data repository to reduce storage and resulting storage costs
Backing up to low-cost disk is fast for backups and restores, however, with longer-term retention, the amount of disk required becomes extremely expensive.
To reduce the amount of disk for long-term retention, deduplication appliances reduce the amount of storage and cost, however the deduplication is performed inline on the way to the disk which slows down backups to about one-third the performance of disk. Also, the data is only stored in deduplicated format resulting in extremely slow restores and VM boots as the data has to be reassembled, or rehydrated, for each request. In addition, deduplication appliances are scale-up storage which only adds storage capacity as data grows, resulting in backup windows that continue to grow as data grows, expensive forklift upgrades, and forced product obsolescence.
ExaGrid Tiered Backup Storage writes directly to disk for the fastest backups, and restores directly from disk for the fastest restores and VM boots. ExaGrid then tiers the long-term retention data to a deduplicated data repository to reduce the amount of retention storage and resulting cost. In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory, and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades, and allows for mixing appliances of different sizes and models in the same scale-out system which eliminates product obsolescence while protecting IT investments up front and over time.
ExaGrid offers the best of both worlds by offering low-cost disk for the fastest backup and restore performance tiered to a deduplicated data repository for the lowest cost retention storage. The scale-out storage architecture provides a fixed-length backup window and is low cost up front and over time.
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our success stories .
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005278/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
